Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial

• Główni autorzy: Guang-Wei Feng (Autor), Zhong-Fang Wang (Autor), Peng He (Autor), Qin-Ying Lan (Autor), Ling Ni (Autor), Ya-Zheng Yang (Autor), Chen-Fei Wang (Autor), Ting-Ting Cui (Autor), Li-Li Huang (Autor), Yong-Qiang Yan (Autor), Zhi-Wei Jiang (Autor), Qing Yang (Autor), Bang-Wei Yu (Autor), Xi Han (Autor), Jing-Jing Chen (Autor), Shu-Yuan Yang (Autor), Lin Yuan (Autor), Ling-Yun Zhou (Autor), Ge Liu (Autor), Ke Li (Autor), Zhen Huang (Autor), Jin-Cun Zhao (Autor), Zhong-Yu Hu (Autor), Zhi-Qiang Xie (Autor)
• Format: Książka
• Wydane: Taylor & Francis Group, 2023-08-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

This was a phase 1 dose-escalation study of ZR202-CoV, a recombinant protein vaccine candidate containing a pre-fusion format of the spike (S)-protein (S-trimer) combined with the dual-adjuvant system of Alum/CpG. A total of 230 participants were screened and 72 healthy adults aged 18-59 years were...